Efficacy and Safety of Salvage Treatment With Dose-dense TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas: a Multicentre,Prospective Clinical Study
Inclusion Criteria:
- Written informed consent
- Age>=18 and <=70years old
- Histological diagnosis of malignant gliomas(WHO III or IV)
- The status of methylation of promotor of MGMT should be detected.
- The time to be enrolled should be more than 90 days after the irradiation.
- The patients with recurrent gliomas were treated with non-dose-dense TMZ therapy
before enrollment.
- Performance status(Karnofsky index)>=60
- Life expectancy more than 3 months
Exclusion Criteria:
- Ages:< 18 years or > 70 years
- Abnormal function of liver or renal(value more than 1.5 fold normal upper limit )
- Blood routing: Hb < 100g/l, WBC < 4.0×109/l; PLT < 100×109/l
- Pregnant or lactating women
- Allergic to administered drugs
- Radiation treatment in the previous 90 days or stereotactic radiation surgery within
60 days before enrollment
- The patients with recurrent gliomas were treated with dose-dense TMZ therapy before
enrollment.
- Life expectancy less than 3 months
- Participation in other clinical trials in the 90previous days before enrollment